Zhong Yuan Bio-Technology Holdings Limited (ZHYBF) P/E Ratio
As of May 23, 2026
TL;DR — ZHYBF P/E ratio is 118.6x
Zhong Yuan Bio-Technology Holdings Limited (ZHYBF) currently trades at a trailing P/E of 118.6x (expensive (growth premium)). Forward P/E is estimated at 109.8x. The implied earnings yield is 0.84%. Above-35x P/E demands very high growth or wide moats. Sensitive to interest-rate changes and any growth disappointment.
Trailing P/E vs Forward P/E
Trailing P/E (TTM)
118.6x
Based on last 12 months of reported EPS
Forward P/E (est)
109.8x
Estimated next 12 months
PEG
N/A
P/E divided by EPS growth — under 1 = cheap
Trailing P/E uses the last 12 months of actual reported earnings — it is the most reliable number because the inputs have already happened. Forward P/E uses consensus analyst estimates for the next 12 months — useful for fast-growing companies whose past earnings understate their future, but vulnerable to estimate revisions. The PEG ratio (P/E divided by earnings growth) is the bridge: a PEG below 1.0 traditionally signals you're paying less per share than the business is growing per share.
10-Year Historical P/E
Over the past decade, ZHYBF has traded at a median P/E of roughly 119.0x. Today's reading of 118.6x is roughly in line with its own historical median. This is a useful relative anchor: paying less than the long-run average implies either a buying opportunity or a structural worry that the market has correctly priced in.
Series illustrated from current P/E. Full 10-year monthly history ships in the upcoming valuation-data ingest.
Industry Comparison
The Consumer Defensive sector median P/E is roughly 19x. ZHYBF at 118.6x is currently ~524% above the sector — a premium that needs to be justified by superior return on capital, higher growth, or wider moat..
Compare ZHYBF against every other Consumer Defensive stock in the full sector list.
Interpreting ZHYBF's P/E
What "Expensive (growth premium)" means here: Above-35x P/E demands very high growth or wide moats. Sensitive to interest-rate changes and any growth disappointment.
Decision rule: a low P/E by itself is not a buy signal. Always check the cash flow statement, the Quality Triple Check (Piotroski / Beneish / Altman) from the fundamentals page, and the intrinsic value (DCF margin of safety) before acting on a multiple alone.
Common pitfalls: trailing P/E can be flattered by one-off tax benefits, share buybacks, or asset sales. Forward P/E can be overstated by overly optimistic analyst estimates. Read at least two of the most recent quarterly earnings calls before treating either as truth.
Related ZHYBF analyses
Frequently asked about ZHYBF P/E
What is ZHYBF's current P/E ratio?↓
ZHYBF's trailing P/E ratio is 118.6x as of May 23, 2026, which we classify as "Expensive (growth premium)". Above-35x P/E demands very high growth or wide moats. Sensitive to interest-rate changes and any growth disappointment.
Is ZHYBF's P/E ratio cheap or expensive?↓
Against the Consumer Defensive sector median of ~19x, ZHYBF's 118.6x is materially above the sector — a premium of about 524%, which needs to be justified by superior growth, returns on capital, or moat width.
What is the difference between trailing and forward P/E?↓
Trailing P/E (TTM) uses the last 12 months of actual earnings — backward-looking but reliable. Forward P/E uses consensus analyst estimates for the next 12 months — more useful for growth stories but vulnerable to estimate revisions. Most value investors anchor on trailing P/E and use forward P/E as a sanity check.
How is P/E related to earnings yield?↓
Earnings yield = 1 / P/E. For ZHYBF at 118.6x P/E, earnings yield is roughly 0.84%. This is comparable to a bond yield: it tells you the "earnings return" you'd get if you bought the whole company at this price.
When is P/E the wrong metric to use?↓
P/E breaks down for companies with negative earnings, heavy non-cash items, one-off events (restructuring, write-downs, tax benefits), banks (where book value and P/B are more appropriate), and high-CapEx commodity businesses (where EV/EBITDA is more comparable). Always cross-check P/E with at least one other valuation lens.